Trigger Point and Tender Point Injections
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical policy governing coverage and medical necessity criteria for trigger point and tender point injections for BCBSNC members; applies to providers seeking reimbursement for these procedures.
Policy re-titled to 'Trigger Point and Tender Point Injections' and policy statement updated to specify coverage when medical criteria are met.
Added CPT codes 20552 and 20553 to the Billing/Coding section.
When Covered section updated to add specific medical necessity criteria and limits (including max 4 injections per muscle per 12 months).
When Not Covered section updated to specifically state botulinum toxin injections are not covered and removed investigational status for imaging guidance.
Policy re-titled to 'Trigger Point and Tender Point Injections' and policy statement updated to state BCBSNC may provide coverage when medical criteria are met.
Trigger point injections using botulinum toxin or botulinum toxin derivatives are not covered.
Added CPT codes 20552 and 20553 to the Billing/Coding section.
Separate reimbursement is not allowed for image guidance.
Coverage Criteria
inv-01: When covered
Covered when ALL of the following are met
inv-03: When Covered (summary)
Covered when BCBSNC determines medical necessity based on medical criteria shown in the policy
inv-02: When not covered / Investigational
Not covered for indications not meeting criteria or specific exclusions
Trigger point injections using botulinum toxin or botulinum toxin derivatives are explicitly excluded from coverage. BCBSNC will deny services for trigger point injections when botulinum toxin or its derivatives are used, and separate reimbursement is not allowed for image guidance associated with these injections as noted in the policy updates.
Trigger point injections using botulinum toxin or botulinum toxin derivatives are not covered. This exclusion is stated in the policy’s When Not Covered section and was reiterated in the policy implementation updates.
Use of trigger point or tender point injections for indications that do not meet the specified medical necessity criteria is considered investigational and therefore not medically necessary. Examples called out in the policy include myofascial pain syndrome that does not meet the criteria, complex regional pain syndrome, abdominal wall pain, and fibromyalgia.
No additional explicit 'not medically necessary' conditions beyond those already stated in the When Not Covered or investigational sections are provided in the cited policy update information.
Billing, Coding, and Payment
Conservative Treatment Requirements
inv-25: Required prior to coverage
Required prior to coverage
Frequency and Quantity Limits
Imaging and Guidance
Verify benefits and prior authorization
Do not assume coverage — verify the member’s benefits and any prior authorization requirements before scheduling trigger point or tender point injections. Inclusion of CPT codes 20552 and 20553 in this policy does not guarantee reimbursement.
Billing code update and image guidance payment rule
When billing for trigger point or tender point injections, report CPT codes 20552 (1–2 muscles) or 20553 (3 or more muscles) as applicable, and do not bill separately for image guidance — separate reimbursement for image guidance is not allowed.
Provider Actions and Documentation
Confirm benefits and authorization
Verify member benefits and any prior authorization requirements before providing trigger point or tender point injections. Inclusion of CPT codes in the policy does not guarantee reimbursement.
- Check the member's benefit booklet and group contract for coverage and prior authorization rules.
Require 6-week trial of conservative therapy
A non-surgical conservative treatment regimen (eg, physical therapy, active exercises, ultrasound, heating/cooling, massage, activity modification) must fail or be infeasible for 6 weeks before trigger point injections are considered.
- Document the 6-week trial or why conservative care was not feasible.
Submit complete medical records if requested
BCBSNC may request medical records to determine medical necessity; letters alone are not sufficient unless they include all specific information needed to make the determination.
- When records are requested, include objective findings that meet the policy criteria (eg, regional pain distribution, palpable taut band with spot tenderness, restricted range of motion, documentation of conservative therapy).
Documentation / policy history noted
The policy records notification and review history, but no additional specific provider documentation requirements are stated in these chunks.
Denial risk if medical necessity criteria not met
Denials may occur if trigger point injections do not meet the policy’s medical necessity criteria (see 'When covered') or if botulinum toxin is used; inclusion of CPT codes does not guarantee reimbursement.
- Ensure all 'When covered' criteria are documented: regional pain distribution, palpable taut band with spot tenderness, restricted range of motion, 6-week conservative therapy trial or infeasibility, part of an active treatment program, and no more than 4 injections per muscle in 12 months.
- Do not use botulinum toxin or its derivatives for trigger point injections (these will be denied).
Botulinum toxin injections excluded
Trigger point injections using botulinum toxin or botulinum toxin derivatives are not covered and will be denied.
Not Covered
NOT COVERED: Trigger point injections using botulinum toxin or botulinum toxin derivatives. The policy implementation updates also clarify that separate reimbursement is not allowed for image guidance used with trigger point injections.
Background
Trigger points are discrete, focal, hyperirritable spots within a taut band of skeletal muscle fibers that produce local and/or referred pain when stimulated. Tender points produce local pain on palpation but lack a taut band and hyperirritability. Injection therapies (including local anesthetic or botulinum toxin in some studies) have been evaluated for these entities, but the policy limits coverage to situations meeting specified medical necessity criteria.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.